These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 29360841)

  • 1. Does directly administered antiretroviral therapy represent good value for money in sub-Saharan Africa? A cost-utility and value of information analysis.
    Uthman RT; Sutton AJ; Jackson LJ; Uthman OA
    PLoS One; 2018; 13(1):e0191465. PubMed ID: 29360841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
    Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
    Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of optimized background therapy plus maraviroc for previously treated patients with R5 HIV-1 infection from the perspective of the Spanish health care system.
    Moreno S; González J; Lekander I; Martí B; Oyagüez I; Sánchez-de la Rosa R; Casado MA
    Clin Ther; 2010 Dec; 32(13):2232-45. PubMed ID: 21316539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa.
    Marseille E; Kahn JG; Mmiro F; Guay L; Musoke P; Fowler MG; Jackson JB
    Lancet; 1999 Sep; 354(9181):803-9. PubMed ID: 10485721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The costs of HIV antiretroviral therapy adherence programs and impact on health care utilization.
    Sansom SL; Anthony MN; Garland WH; Squires KE; Witt MD; Kovacs Andrea A; Larsen RA; Valencia R; Pals SL; Hader S; Weidle PJ; Wohl AR
    AIDS Patient Care STDS; 2008 Feb; 22(2):131-8. PubMed ID: 18260804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of integrating methadone maintenance and antiretroviral treatment for HIV-positive drug users in Vietnam's injection-driven HIV epidemics.
    Tran BX; Ohinmaa A; Duong AT; Nguyen LT; Vu PX; Mills S; Houston S; Jacobs P
    Drug Alcohol Depend; 2012 Oct; 125(3):260-6. PubMed ID: 22436971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.
    Phillips AN; Bansi-Matharu L; Cambiano V; Ehrenkranz P; Serenata C; Venter F; Pett S; Flexner C; Jahn A; Revill P; Garnett GP
    Lancet Glob Health; 2021 May; 9(5):e620-e627. PubMed ID: 33770513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. US cost-utility model of lenacapavir plus optimized background regimen (OBR) vs fostemsavir plus OBR and ibalizumab plus OBR for people with HIV with multidrug resistance.
    Vardanega V; New E; Mezzio D; Eddowes LA
    J Manag Care Spec Pharm; 2024 Sep; 30(9):1001-1012. PubMed ID: 39213144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of laboratory monitoring for management of HIV treatment in sub-Saharan Africa: a model-based analysis.
    Hamers RL; Sawyer AW; Tuohy M; Stevens WS; Rinke de Wit TF; Hill AM;
    AIDS; 2012 Aug; 26(13):1663-72. PubMed ID: 22695297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.
    Brogan AJ; Talbird SE; Cohen C
    Value Health; 2011; 14(5):657-64. PubMed ID: 21839403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.
    Phillips AN; Bansi-Matharu L; Venter F; Havlir D; Pozniak A; Kuritzkes DR; Wensing A; Lundgren JD; Pillay D; Mellors J; Cambiano V; Jahn A; Apollo T; Mugurungi O; Ripin D; Da Silva J; Raizes E; Ford N; Siberry GK; Gupta RK; Barnabas R; Revill P; Cohn J; Calmy A; Bertagnolio S
    Lancet HIV; 2020 Mar; 7(3):e193-e200. PubMed ID: 32035041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The REVAMP trial to evaluate HIV resistance testing in sub-Saharan Africa: a case study in clinical trial design in resource limited settings to optimize effectiveness and cost effectiveness estimates.
    Siedner MJ; Bwana MB; Moosa MS; Paul M; Pillay S; McCluskey S; Aturinda I; Ard K; Muyindike W; Moodley P; Brijkumar J; Rautenberg T; George G; Johnson B; Gandhi RT; Sunpath H; Marconi VC
    HIV Clin Trials; 2017 Jul; 18(4):149-155. PubMed ID: 28720039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. When to start antiretroviral therapy in resource-limited settings.
    Walensky RP; Wolf LL; Wood R; Fofana MO; Freedberg KA; Martinson NA; Paltiel AD; Anglaret X; Weinstein MC; Losina E;
    Ann Intern Med; 2009 Aug; 151(3):157-66. PubMed ID: 19620143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "Conditional scholarships" for HIV/AIDS health workers: educating and retaining the workforce to provide antiretroviral treatment in sub-Saharan Africa.
    Bärnighausen T; Bloom DE
    Soc Sci Med; 2009 Feb; 68(3):544-51. PubMed ID: 19081662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effectiveness and cost-effectiveness of community-based support for adolescents receiving antiretroviral treatment: an operational research study in South Africa.
    Fatti G; Jackson D; Goga AE; Shaikh N; Eley B; Nachega JB; Grimwood A
    J Int AIDS Soc; 2018 Feb; 21 Suppl 1(Suppl Suppl 1):. PubMed ID: 29485714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effectiveness and cost-effectiveness of 3- vs. 6-monthly dispensing of antiretroviral treatment (ART) for stable HIV patients in community ART-refill groups in Zimbabwe: study protocol for a pragmatic, cluster-randomized trial.
    Fatti G; Ngorima-Mabhena N; Chirowa F; Chirwa B; Takarinda K; Tafuma TA; Mahachi N; Chikodzore R; Nyadundu S; Ajayi CA; Mutasa-Apollo T; Mugurungi O; Mothibi E; Hoffman RM; Grimwood A
    Trials; 2018 Jan; 19(1):79. PubMed ID: 29378662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contemporary issues on the epidemiology and antiretroviral adherence of HIV-infected adolescents in sub-Saharan Africa: a narrative review.
    Adejumo OA; Malee KM; Ryscavage P; Hunter SJ; Taiwo BO
    J Int AIDS Soc; 2015; 18(1):20049. PubMed ID: 26385853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Where to deploy pre-exposure prophylaxis (PrEP) in sub-Saharan Africa?
    Verguet S; Stalcup M; Walsh JA
    Sex Transm Infect; 2013 Dec; 89(8):628-34. PubMed ID: 23912819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economics of switching to second-line antiretroviral therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda and Kenya.
    Simpson KN; Baran RW; Kirbach SE; Dietz B
    Value Health; 2011 Dec; 14(8):1048-54. PubMed ID: 22152173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effectiveness and cost implications of task-shifting in the delivery of antiretroviral therapy to HIV-infected patients: a systematic review.
    Mdege ND; Chindove S; Ali S
    Health Policy Plan; 2013 May; 28(3):223-36. PubMed ID: 22738755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.